Maintenance of Response With up to 4 Years of Continuous Guselkumab Treatment: Results From the VOYAGE 1 Phase 3 Trial

Christopher Em Griffiths; Kim Papp; Mengsa Song; Megan Miller; Yin You; Y-K Shen; Chenglong Han; Andrew Blauvelt

doi:10.25251/skin.3.supp.17

Related publications

Article2018

Maintenance of Response With Guselkumab for up to 3 Years’ Treatment in the Phase 3 VOYAGE 1 Trial of Patients With Plaque Psoriasis

Christopher Em Griffiths, KA Papp, Michael Song, B. Randazzo, S Li, Y-K Shen, Chenglong Han, Andrew Blauvelt

Article2021

AB0532 MAINTENANCE OF RESPONSE THROUGH 5 YEARS OF CONTINUOUS GUSELKUMAB TREATMENT: RESULTS FROM THE PHASE-3 VOYAGE 1 TRIAL

Christopher Em Griffiths, Kim Papp, Michael Song, Megan Miller, Yin You, Yaung‐Kaung Shen, Andrew Blauvelt

Article2019

Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials

Kristian Reich, Christopher Em Griffiths, Kenneth B. Gordon, Kim Papp, Michael Song, B. Randazzo, Shu Li, Yaung‐Kaung Shen, Chenglong Han, Alexa B. Kimball, April W. Armstrong, Peter Foley, Andrew Blauvelt

Article2020

Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1

Christopher Em Griffiths, Kim Papp, Michael Song, Megan Miller, Yin You, Yaung‐Kaung Shen, Chenglong Han, Andrew Blauvelt

Article2021

28095 Long-term safety of guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials with up to 5 years of treatment

Andrew Blauvelt, Kenneth B. Gordon, Christopher Em Griffiths, Kim Papp, Peter Foley, Michael Song, Megan Miller, Yaung‐Kaung Shen, Paraneedharan Ramachandran, Kristian Reich